Effect of Semaglutide in Patients With Psoriasis and Obesity

Plain-language guide to NCT06937060: phase 3 interventional trial of Semaglutide, psoriasis and psoriatic arthritis, 14 participants. Who took part, design and what was measured.

Key Facts

Registry ID: NCT06937060
Phase: phase 3
Status: recruiting participants
Start: 2025-03-20
Completion (planned or actual): 2026-07-31
Participants: 14 (estimated)
Design: na, open label (everyone knows who gets what), treatment
Conditions studied: Psoriasis (PsO); Obesity and Overweight
Results posted: not yet

What This Study Did, in Plain Language

What Was Tested

This registered phase 3 trial tested Semaglutide for psoriasis and psoriatic arthritis.

Obesity is well known to be an important comorbidity of psoriasis.

It gives rise to higher risk of psoriatic arthritis, more severe disease and also poorer response to biologics.

It had 1 arm (groups): Active (alternative intervention) (experimental).

The registry classes the interventions as biological.

Who Took Part

The registry lists 14 planned participants were the target.

It was open to people of any sex aged from 18 years up to 75 years.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: A clinical diagnosed Psoriatic disease of at least 6 months before signing of informed consent. \>18 years of age, up to 75 years of age. Moderate to severe psoriasis (PASI score 5-10= moderate, \>10 = severe). Ability to comply with stud.

The full record lists 8 inclusion and 15 exclusion criteria; among the exclusions: patients who refuse to give consent; contraindication to use of glp1 ra; history of pancreatitis.

How the Study Was Run

The set-up was single-group and open-label.

Everyone knew when Semaglutide was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

Everyone received the same intervention, so there was no separate comparison group inside the trial.

It started in 2025-03-20 with completion listed for 2026-07-31.

It ran at 1 site in Hong Kong.

Its stated primary purpose is treatment.

What Was Measured

The main thing measured (primary outcome): Change in mean Psoriasis Area and Severity Index (PASI) before and after semaglutide treatment (time frame: 36 weeks).

What This Means in Plain Language

Put simply, this is a phase 3 trial of Semaglutide in 14 people with psoriasis and psoriatic arthritis.

Its size is small, so on its own it can only give an early look.

It is still recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Semaglutide compound page, Psoriasis and psoriatic arthritis research.

Our Notes on the Compound

Semaglutide: The active ingredient in several prescription GLP-1 receptor agonist medicines (Ozempic, Wegovy, oral tablets).

Source: ClinicalTrials.gov record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.